[Study on bioavilability of oxymatrine-phospholipid complex in rats].
OBJECTIVE
To study the plasma concentration-time curve, pharmacokinetic parameters and bioavilability of oxymatrine-phospholipid complex and to compare with oxymatrine in rats.


METHODS
Rats were given oxymatrine-phospholipid 100 mg x kg(-1). Blood samples were collected at different times after oral administration. The internal standard was cimetidine. Protein in plasma was precipitated with merhanol and centrifuged at high speed. The supernatant was directly injected and assayed by CE method. The running buffer was 0.04 mol x L(-1) Tris-10 mmol x L(-1) sodium phosphate monobasic-40% isopropanol pH to 7.6 with phosphoric acid. The wavelength of detection was 205 nm.


RESULTS
The AUC of oxymatrine and oxymatrine-phospholipid complex were 4.52 mg x mL(-1) x h(-1) and 6.21 mg x mL(-1) x h(-1), respectively. The oxymatrine-phospholipid bioavailability enhanced 1.4 times.


CONCLUSIONS
It is concluded that after oral administration of oxymatrine-phospholipid complex in rats the bioavailability of oxymatrine is increased greatly. This is mainly due to an obvious improvement of the lipophilic property of oxymatrine-phospholipid complex compared with oxymatrine material and an increase in gastrointestinal absorption.
Han
Yu-Mei
YM
School of Bioengineering, Chongqing Institute of Technology, Chongqing 400050, China. hym@cqit.edu.cn
Yan
Dan
D
Yuan
Hai-Long
HL
D000284:Administration, Oral; D000470:Alkaloids / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D019540:Area Under Curve; D001682:Biological Availability; D008297:Male; D010743:Phospholipids / Q000737:chemistry*; D010946:Plants, Medicinal / Q000737:chemistry; D011807:Quinolizines / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D029909:Sophora / Q000737:chemistry; D000093842:Matrines
D000470:Alkaloids; D000889:Anti-Arrhythmia Agents; D010743:Phospholipids; D011807:Quinolizines; C037573:oxymatrine; D000093842:Matrines